Camrelizumab is a monoclonal antibody used in the treatment of various cancers, including non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), classical Hodgkin's lymphoma, and nasopharyngeal carcinoma. It functions by binding to the PD-1 receptor on T-cells, blocking its interaction with PD-L1/PD-L2 and thereby unleashing the immune system's response against cancer cells, enabling T-cells to detect and destroy tumor cells more effectively.

Approved in several countries, particularly China, it is administered intravenously and is indicated for patients with advanced or recurrent disease after prior treatments such as chemotherapy or radiation. It is often used in combination with chemotherapy or other immunotherapies. Clinical studies demonstrate improved overall survival, tumor control, and durable responses in certain patients. It is also under investigation in multiple clinical trials for additional cancer types.

However, treatment with camrelizumab may cause immune-related adverse effects, such as rash, diarrhea, hepatitis, pneumonitis, or endocrinopathies, requiring close monitoring during therapy.